Meeder Asset Management Inc Prothena Corp Public LTD CO Transaction History

Meeder Asset Management Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$42.11 - $73.26 $76,345 - $132,820	-1,813 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$48.2 - $78.89 $10,555 - $17,276	219 Added 13.74%	1,813 $129,000
Q2 2021 Aug 09, 2021	BUY	$21.63 - $57.65 $34,478 - $91,894	1,594 New	1,594 $82,000
Q2 2020 Aug 11, 2020	SELL	$9.56 - $12.51 $23,833 - $31,187	-2,493 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$7.54 - $15.77 $17,568 - $36,744	2,330 Added 1429.45%	2,493 $26,000
Q4 2019 Feb 13, 2020	SELL	$7.48 - $17.01 $57,797 - $131,436	-7,727 Reduced 97.93%	163 $3,000
Q3 2019 Oct 17, 2019	BUY	$6.89 - $10.45 $29,613 - $44,914	4,298 Added 119.65%	7,890 $62,000
Q2 2019 Aug 05, 2019	BUY	$8.85 - $12.49 $31,789 - $44,864	3,592 New	3,592 $37,000
Q4 2018 Jan 17, 2019	SELL	$8.73 - $13.74 $803 - $1,264	-92 Closed	0 $0
Q3 2018 Nov 02, 2018	BUY	$12.7 - $15.79 $1,168 - $1,452	92 New	92 $0
Q2 2018 Jul 24, 2018	SELL	$10.99 - $44.21 $274 - $1,105	-25 Closed	0 $0
Q1 2018 May 03, 2018	SELL	$27.95 - $45.04 $2,319 - $3,738	-83 Reduced 76.85%	25 $1,000
Q4 2017 Feb 02, 2018	BUY	$35.44 - $63.76 $3,827 - $6,886	108	108 $4,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $659M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.